Motley Fool Health-Care Analyst David Williamson discusses the earnings report and conference call released yesterday from Sarepta, and talks about why it may be the next biotech company to keep your eye on. Like any biotech company in the development stage, Sarepta didn't have a whole lot of earnings to report, but the conference call was full of great information. Williamson breaks down all the things he liked, and some of the things he didn't, from this exciting company's quarter.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.